BCAX | Ticker Profile - Titan Protect

BCAX

Bicara Therapeutics Inc.

Healthcare · Biotechnology · NGM

$20.00

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.4B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-5.94

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-32.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$31.00

+55% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 13 analysts covering this stock

About Bicara Therapeutics Inc.

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

https://www.bicara.com

Country: United States Employees: 103 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.354

Positive but modest risk-adjusted returns

Kelly Fraction

0.0188

Marginal edge — very small allocation suggested

Calmar Ratio

-0.063

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-4.3%

Historical annualised return based on price data

Max Drawdown

-67.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

133

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$24.25

18% below the year high

52W Low

$8.48

136% above the year low

Avg Volume

555,388

Average daily shares traded — higher means easier to buy and sell

Short Ratio

19.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

20.9%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.77

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.28

Conservative use of debt — low financial risk

Current Ratio

13.85

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

13.72

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-68,385,248

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-157,315,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$46.00

Target Median

$31.00

Target Low

$16.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go